Detail akcie BioAffinity Rg online

Business Summary: bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, bioAffinity Technologies Inc revenues decreased 36% to $4.6M. Net loss increased 94% to $11.8M. Revenues reflect Diagnostic R&D segment decrease from $9K to $0K. Higher net loss reflects Other expense increase from $10K to $497K (expense), Depreciation & Amortization increase from $151K to $381K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$16.34 to -$14.72.